Neuraxis

Neuraxis Capital Intensity

The Capital Intensity Ratio of Neuraxis (NRXS) as of Nov 16, 2026 is 179.42 %. In the previous year, Capital Intensity Ratio was 177.13 % — a change of 1.29% (higher).

Capital Intensity

179.42 %

YoY

1.29%

Last updated:

Capital Intensity Ratio of Neuraxis is 2025 179.42 % . Capital Intensity Ratio of Neuraxis was 2024 177.13 % . It decreases by 1.29% higher compared to the previous year.

The Neuraxis Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2020
144.52 USD
Jan 1, 2021
27.95 USD
Jan 1, 2022
55.15 USD
Jan 1, 2023
20.71 USD
Jan 1, 2024
177.13 USD
Jan 1, 2025
179.42 USD
The Neuraxis Capital Intensity history
YEARCapital IntensityYoY
179.42 %+1.29%
177.13 %+755.25%
20.71 %-62.45%
55.15 %+97.35%
27.95 %-80.66%
144.52 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuraxis Stock analysis

What does Neuraxis do? NeurAxis, Inc. generates revenue through the development and commercialization of neuromodulation therapies targeting chronic conditions in pediatric patients. The company's primary product, the B-Stim device, is designed for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children aged 11-18. The FDA pipeline includes additional indications such as chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome, which expand the potential market reach of their PENFS technology. The company's focus on pediatric applications differentiates its offerings within the neuromodulation sector. The Percutaneous Electrical Nerve Field Stimulation (PENFS) technology underpins both the B-Stim and IB-Stim systems, which are specifically tailored for pediatric use. These devices are intended for patients 11-18 years of age with functional abdominal pain linked to IBS, positioning NeurAxis to address unmet medical needs in adolescent healthcare. The FDA's involvement in the pipeline process ensures regulatory alignment for expanding indications, which supports market adoption and potential revenue streams. NeurAxis targets healthcare providers and pediatric specialists who treat chronic conditions in adolescents. The company's products are positioned to address functional gastrointestinal disorders and related symptoms, offering an alternative to traditional pharmacological treatments. By focusing on specific age groups and medical indications, NeurAxis aims to capture a niche segment within the broader neuromodulation market. Neuraxis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuraxis stock

Capital Intensity Ratio of Neuraxis is 179.42 % in 2025.

Capital Intensity Ratio of Neuraxis changed from 177.13 % to 179.42 %, representing a 1.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Neuraxis since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Neuraxis with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Neuraxis

All Key Metrics — Neuraxis